Oak Longevity Review: The $167 That Is Not in Its Own Catalogue

$250 a month for compounded semaglutide and $300 for compounded tirzepatide, both as 30-day supplies, with the consultation and shipping included at no charge. Those are the two products Oak's own funnel opens with, read directly from its checkout catalogue on August 9, 2026. What it is not is $167, the number on the product page. Nothing in Oak's catalogue costs $167 a month — not at any dose, not at any of the nine plan lengths, not from any of the five pharmacies it dispenses through.

Nowhere that can be checked, and that is the finding. Oak's checkout publishes its entire priced catalogue: 566 weight-loss products, each with its own days-supply, dose, pharmacy and price. Every one was divided by its own supply length and tested against $167. The cheapest thirty-day compounded semaglutide in the whole catalogue is $205, for the smallest microdose. The cheapest per-month equivalent hidden inside a prepay block is about $186. The product the funnel actually quotes is $250. The "$167/mo" on the product page carries an asterisk, and there is no footnote anywhere on that page for the asterisk to lead to.

On one pharmacy line, yes — and that line is the default, which is why the figures above are $250 and $300. Oak's Greenwich products hold at $250 for semaglutide across every strength from 0.2 mg to 2.3 mg, and $300 for tirzepatide from 1.5 mg to 13.5 mg. On the other four lines in the same catalogue it is plainly untrue: one runs $225, $225, $275, $300, $350 as the dose climbs; another reaches $510 for tirzepatide. Oak's own checkout FAQ says the quiet part out loud — "every step increase in dosage is approximately $50 - $75 more" — and its Terms warn that the fee "may change… based on changes in dosage". You are not told which pharmacy you will get.

At checkout, yes; in the Terms of Use, no. The comparison table on Oak's weight-loss page prints "Membership Fees — None", and the checkout backs that up in the only way that matters to your card: the asynchronous consult, the scheduled video visit and the instant visit all return a fee of $0.00, and standard and expedited shipping both return $0.00 too. But the Terms of Use say something different — "patients are charged a membership fee for a Provider consult", of which "$40 for synchronous (video)" goes to the clinician. The reconciliation is that the fee is a slice of the drug price rather than an addition to it, so nothing is added to the figures here. Two of Oak's own documents still describe the same product in incompatible ways.

Oak's own pages give three different answers, so assume yes and check your portal. The programme description in the checkout says: "Billed monthly on a non-recurring basis with no subscription, you are not auto charged and choose to renew payment each month without penalty." The FAQ served from the very same API response says: "you will automatically be charged after your approval and you agree to pay the final price at the time of prescribing by the doctor." And the Terms of Use say most prescriptions "are configured as a subscription that will renew on a recurring basis" and that Oak "will charge your form of payment on file". The checkout's own configuration flag for charging everything up front is set to true.

$3,000 for semaglutide and $3,600 for tirzepatide on the flat default line, twelve 30-day supplies with nothing added for consultations or shipping. That is a genuinely competitive figure and it does not move when your dose does — provided you stay on that line. If you are dispensed from one of the other pharmacies in Oak's catalogue, a maintenance dose is $290 to $350 for semaglutide and up to $510 for tirzepatide, which is $4,200 and $6,120 a year. The multi-month blocks lower it further — $1,200 buys 168 days of the lowest semaglutide dose — but they are paid up front and nothing is refundable.

Everywhere, including Washington, D.C. This comes from Oak's own checkout rather than a marketing claim: the shippable-states table returns fifty-one records, one for each state plus D.C., and every one is flagged active. Better still, not one of them is flagged as requiring a synchronous visit, so the asynchronous route — fill in the intake, upload your photos and ID, have a clinician review it — is available in all of them. A video visit remains available anywhere if you want one, at no charge.

Almost certainly not, and Oak sets this out in capital letters. Its Terms of Use state that "ANY APPLICABLE FEES AND OTHER CHARGES ARE NOT REFUNDABLE IN WHOLE OR IN PART", and the checkout adds that "Refunds are not available after approval". Cancelling stops future charges — you can do it from the patient portal and Oak aims to act within 24 hours — but it does not undo one. That interacts badly with the pricing structure: you agree at checkout to pay whatever the doctor ultimately prescribes, the checkout warns that the "Final charge may not be final", and once approval lands the money is gone. If you are buying a multi-month block, you are committing several hundred dollars to a drug a meaningful number of people stop within two months.

No. Oak's catalogue prices Mounjaro at $1,200, Ozempic at $1,250, Zepbound at $1,350 and Wegovy at $1,500 for a 30-day supply. Eli Lilly and Novo Nordisk both sell those exact products direct to self-pay patients through their own pharmacies at a fraction of those prices, and any telehealth prescriber can send your prescription there. The compounded products are what Oak is actually competitive at; the branded listings look like a service of last resort priced as though nobody would check.

No. The live warning-letter index was queried on August 9, 2026 as "oak longevity", "oaklovesyou", "oak longevity holdings" and the deliberately broad "oak", plus its two named affiliate corporations. Every query returned its full result set with no truncation. The broad search returned 99 letters, and all 99 were re-checked against the company column: the only two containing the word are Red Oak Instruments and Mountain Oak Vapors, neither of which is this company, and neither is filed here on the strength of a shared word. A positive control returned SkinnyRx's February 2026 letter in the same pass, so the absence is a result rather than a failed query.